91 related articles for article (PubMed ID: 1496654)
1. Urinary tissue type plasminogen activator and plasminogen activator inhibitor in renal transplant patients.
Ikegami M; Ishii T; Uemura T; Kunikata S; Matsuura T; Akiyama T; Kurita T
Transplant Proc; 1992 Aug; 24(4):1547-8. PubMed ID: 1496654
[No Abstract] [Full Text] [Related]
2. Tissue-type plasminogen activator and its inhibitor in human glomerulonephritis.
Aya N; Yoshioka K; Murakami K; Hino S; Okada K; Matsuo O; Maki S
J Pathol; 1992 Mar; 166(3):289-95. PubMed ID: 1381427
[TBL] [Abstract][Full Text] [Related]
3. Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype.
Swiercz R; Wolfe JD; Zaher A; Jankun J
Clin Cancer Res; 1998 Apr; 4(4):869-77. PubMed ID: 9563880
[TBL] [Abstract][Full Text] [Related]
4. A molecular variant of plasminogen activator inhibitor of rat decidual tissue.
Tarachand U; Pawse AR
Biochem Mol Biol Int; 1995 Dec; 37(6):1037-45. PubMed ID: 8747533
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activators and plasminogen activator inhibitors in gingival crevicular fluid of cyclosporin A-treated patients.
Buduneli N; Buduneli E; Ciotanar S; Atilla G; Lappin D; Kinane D
J Clin Periodontol; 2004 Jul; 31(7):556-61. PubMed ID: 15191592
[TBL] [Abstract][Full Text] [Related]
6. Occurrence of components of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue.
Costantini V; Zacharski LR; Memoli VA; Kudryk BJ; Rousseau SM; Stump DC
Cancer Res; 1991 Jan; 51(1):354-8. PubMed ID: 1846311
[TBL] [Abstract][Full Text] [Related]
7. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
Allan EH; Martin TJ
J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
[TBL] [Abstract][Full Text] [Related]
8. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activation system of the platelets.
Park S
Rinsho Byori; 1992 Mar; Suppl 92():131-43. PubMed ID: 1583771
[No Abstract] [Full Text] [Related]
10. [Curative machanism of Shenle capsule on 5/6 nephrectomy rats].
Wei RB; Zhang WX; Chen XM
Zhongguo Zhong Yao Za Zhi; 2004 Aug; 29(8):770-3. PubMed ID: 15506291
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator inhibitor 1 in renal fibrin deposits of human nephropathies.
Rondeau E; Mougenot B; Lacave R; Peraldi MN; Kruithof EK; Sraer JD
Clin Nephrol; 1990 Feb; 33(2):55-60. PubMed ID: 2107050
[TBL] [Abstract][Full Text] [Related]
12. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
13. Spitz naevi may express components of the plasminogen activation system.
Ferrier CM; Van Geloof WL; Straatman H; Van De Molengraft FJ; Van Muijen GN; Ruiter DJ
J Pathol; 2002 Sep; 198(1):92-9. PubMed ID: 12210068
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitors type 1 and type 2 and plasminogen activators in amniotic fluid during pregnancy.
Estellés A; Gilabert J; Andrés C; España F; Aznar J
Thromb Haemost; 1990 Oct; 64(2):281-5. PubMed ID: 2125378
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolytic changes and the influence of the early perfusate in orthotopic liver transplantation with intraoperative aprotinin treatment.
Himmelreich G; Kierzek B; Neuhaus P; Slamer KJ; Riess H
Transplant Proc; 1991 Jun; 23(3):1936-7. PubMed ID: 1712137
[No Abstract] [Full Text] [Related]
16. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
[TBL] [Abstract][Full Text] [Related]
17. [Tissue type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI) in transplanted kidneys].
Ikegami M; Nagano T; Hara Y; Negita M; Imanishi M; Ishii T; Uemura T; Kunikata S; Kanda H; Matsuura T
Nihon Hinyokika Gakkai Zasshi; 1995 May; 86(5):991-5. PubMed ID: 7596085
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor type 1: biochemistry and evidence for modulation of fibrinolysis in vivo.
Krishnamurti C; Alving BM
Semin Thromb Hemost; 1992 Jan; 18(1):67-80. PubMed ID: 1374195
[No Abstract] [Full Text] [Related]
19. Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and protein in rat osteoblast-like cells.
Allan EH; Zeheb R; Gelehrter TD; Heaton JH; Fukumoto S; Yee JA; Martin TJ
J Cell Physiol; 1991 Oct; 149(1):34-43. PubMed ID: 1834680
[TBL] [Abstract][Full Text] [Related]
20. On the reversible interaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator and with urokinase-type plasminogen activator.
Lijnen HR; Van Hoef B; Collen D
J Biol Chem; 1991 Mar; 266(7):4041-4. PubMed ID: 1900284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
